Papers/PMID:39565038
Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.
Nutritional neuroscience2025The record
2 findings drawn from this paper, on 1 compound across 2 endpoints.
What it reported
How to read these marksWhat moved
2 findings
resveratrol — decreases malondialdehyde (circulating)
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Resveratrol treatment significantly decreased TNF-α (P < 0.001), and MDA (P < 0.001) compared to the placebo.”
Quoted verbatim from Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- 500 mg/day
- Population
- patients with multiple sclerosis (MS)
resveratrol — decreases tumour necrosis factor alpha concentration
PreliminaryGrade D, Preliminary. Non-human or in vitro only.Finding“Resveratrol treatment significantly decreased TNF-α (P < 0.001), and MDA (P < 0.001) compared to the placebo.”
Quoted verbatim from Effects of resveratrol supplementation on inflammatory markers, fatigue scale, fasting blood sugar and lipid profile in relapsing-remitting multiple sclerosis patients: a double-blind, randomized placebo-controlled trial.. - Study
- RCT
- Duration
- 8 weeks
- Dose
- 500 mg/day
- Population
- patients with multiple sclerosis (MS)